PPCB (NASDAQ:PPCB) Announces Quarterly Earnings Results

PPCB (NASDAQ:PPCB) announced its quarterly earnings data on Thursday. The company reported ($0.28) EPS for the quarter, FiscalAI reports.

PPCB Stock Performance

PPCB stock traded down $0.01 during mid-day trading on Friday, hitting $0.07. The company had a trading volume of 3,369,301 shares, compared to its average volume of 1,433,077. The stock has a market cap of $1.08 million, a PE ratio of -0.01 and a beta of 3.59. PPCB has a 1 year low of $0.06 and a 1 year high of $10.81. The business has a fifty day moving average of $0.11.

Shares of PPCB are set to reverse split before the market opens on Monday, May 18th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, May 17th.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of PPCB from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About PPCB

Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.